Top KRX Growth Companies With High Insider Ownership

The South Korean stock market recently ended a two-day winning streak, with the KOSPI index experiencing a sharp decline amid losses in the energy and industrial sectors. As global forecasts remain mixed to lower, especially for technology shares, investors are increasingly focused on identifying resilient growth companies. In this environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations. Here are three top KRX growth companies that stand out due to their substantial insider ownership.

Top 10 Growth Companies With High Insider Ownership In South Korea

Name	Insider Ownership	Earnings Growth
ALTEOGEN (KOSDAQ:A196170)	26.6%	73.1%
Fine M-TecLTD (KOSDAQ:A441270)	17.1%	36.4%
Global Tax Free (KOSDAQ:A204620)	18.1%	72.4%
Seojin SystemLtd (KOSDAQ:A178320)	29.8%	58.7%
INTEKPLUS (KOSDAQ:A064290)	16.3%	77.4%
Park Systems (KOSDAQ:A140860)	33%	36.6%
Vuno (KOSDAQ:A338220)	19.5%	105%
UTI (KOSDAQ:A179900)	33.1%	122.7%
HANA Micron (KOSDAQ:A067310)	20%	97.4%
Techwing (KOSDAQ:A089030)	18.7%	77.8%

Click here to see the full list of 80 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Hana Materials (KOSDAQ:A166090)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Hana Materials Inc., with a market cap of ₩919.66 billion, manufactures and sells silicon electrodes and rings in South Korea.

Operations: Revenue Segments (in millions of ₩): silicon electrodes: ₩200000, rings: ₩150000

Insider Ownership: 12.5%

Hana Materials, a growth company with high insider ownership in South Korea, is forecast to see its revenue grow 20.2% per year, outpacing the market's 10.2%. Earnings are expected to jump by 40.37% annually over the next three years. However, despite this strong growth outlook, profit margins have decreased from 25.1% to 11.6%, and the company's return on equity is projected to be low at 16.2%. Analysts predict a stock price increase of 45.6%.

• Take a closer look at Hana Materials' potential here in our earnings growth report.
• Our expertly prepared valuation report Hana Materials implies its share price may be too high.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc., a biotechnology company, develops long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars with a market cap of ₩17.03 trillion.

Operations: The company's revenue segments include the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

Insider Ownership: 26.6%

ALTEOGEN Inc. is trading at 67.8% below its estimated fair value and recently became profitable, with earnings forecast to grow 73.06% annually, outpacing the South Korean market's 29.5%. The company's revenue is expected to increase by 48.3% per year, significantly faster than the market average of 10.2%. Despite high volatility and past shareholder dilution, ALTEOGEN's recent MFDS approval for Tergase® marks a significant milestone as it transitions to a commercial-stage company with superior product offerings in biologics.

• Delve into the full analysis future growth report here for a deeper understanding of ALTEOGEN.
• Our valuation report unveils the possibility ALTEOGEN's shares may be trading at a premium.

ST PharmLtd (KOSDAQ:A237690)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ST Pharm Co., Ltd. offers custom manufacturing services for active pharmaceutical ingredients and intermediates both in South Korea and internationally, with a market cap of ₩1.86 billion.

Operations: ST Pharm Co., Ltd.'s revenue segments include Raw Drug Manufacturing at ₩251.86 billion and Clinical Trial Site Consignment Research Institute at ₩34.40 billion.

Insider Ownership: 12.8%

ST Pharm Ltd. is expected to see its revenue grow at 16.8% annually, faster than the South Korean market's 10.2%. Earnings are forecast to rise by 33.6% per year, surpassing the market average of 29.5%. Despite recent high volatility and past shareholder dilution, the stock trades at 59.8% below its estimated fair value with analysts predicting a price increase of 22.8%. The company has also shown substantial profit growth over the past five years, averaging 66.7% annually.

• Get an in-depth perspective on ST PharmLtd's performance by reading our analyst estimates report here.
• The analysis detailed in our ST PharmLtd valuation report hints at an deflated share price compared to its estimated value.

Taking Advantage

• Gain an insight into the universe of 80 Fast Growing KRX Companies With High Insider Ownership by clicking here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com